NILE Study Results Demonstrating Guardant360’s High Concordance to Tissue Testing in Advanced NSCLC Published in Clinical Cancer Research

    NEXT STORY
    Helix BioPharma Corp. Reports Voting Results
    PREV STORY
    Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease

    author_avatar
    NASDAQ Market News

    Foamix to Host Conference Call & Webcast to Discuss Topline Results From Phase 2 Study of FDX-104 in Acneiform Rash Associated With Targeted Antibody Treatments for Colon and Head and Neck Cancers

    REHOVOT, Israel and BRIDGEWATER, N.J., Dec. 2, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. ...

    author_avatar
    NASDAQ Market News

    R-PHARM US Expands its Oncology Asset Portfolio with the Exclusive License and Distribution Rights to episil® in the United States 

    PRINCETON, N.J., April 21, 2016 (GLOBE NEWSWIRE) -- R-PHARM US today announced it has ...

    author_avatar
    NASDAQ Market News